کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
6124351 1219990 2008 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Pharmacokinetic-pharmacodynamic target attainment analysis of cefozopran in Japanese adult patients
موضوعات مرتبط
علوم زیستی و بیوفناوری ایمنی شناسی و میکروب شناسی میکروبیولوژی و بیوتکنولوژی کاربردی
پیش نمایش صفحه اول مقاله
Pharmacokinetic-pharmacodynamic target attainment analysis of cefozopran in Japanese adult patients
چکیده انگلیسی
This study aimed to perform a pharmacokinetic-pharmacodynamic (PK-PD) target attainment analysis to create a dosing strategy for cefozopran in Japanese adult patients. A total of 145 plasma concentration samples from 32 adult patients were used for a population pharmacokinetic modeling and Monte Carlo simulation to assess the probability of attaining the PK-PD target (70% of the time above the minimum inhibitory concentration for the bacterium). The final population pharmacokinetic model was based on a two-compartment model, and creatinine clearance (Clcr) and body weight (BW) were the most significant covariates: Cl(l/h) = 0.0263 × Clcr + 1.49, Vc(l) = 0.185 × BW0.931, Q(l/h) = 4.55, Vp(l) = 5.86, where Cl is the clearance, Vc is the volume of distribution of the central compartment, Q is the intercompartmental clearance, and Vp is the volume of distribution of the peripheral compartment. The Monte Carlo simulation demonstrated that 1 g q 12 h achieved a PK-PD target attainment probability of ≥ 85% against Escherichia coli, Klebsiella pneumoniae, and Streptococcus pneumoniae isolates. However, against Haemophilus influenzae and Pseudomonas aeruginosa isolates, 1 g q 8 h and (2 g, 1 g, 1 g) q 8 h were required to achieve a high probability, which value varied with the Clcr and BW of the patient. These results provide a PK-PD-based strategy for tailoring cefozopran regimens in Japanese adult patients.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Infection and Chemotherapy - Volume 14, Issue 2, 2008, Pages 130-136
نویسندگان
, , , , , , ,